Plasmid DNA Contract Manufacturing Market Size, Share & Trends Analysis Report By Application (Cell & Gene Therapy, Immunotherapy), By Therapeutic Area (Cancer, Infectious Diseases), By End-user, By Region, And Segment Forecasts, 2023 - 2030
This report can be delivered to the clients within 3 Business Days
Plasmid DNA Contract Manufacturing Market Growth & Trends
The global plasmid DNA contract manufacturing market size is expected to reach USD 1,117.5 million by 2030, registering a CAGR of 19.3%, according to a new report by Grand View Research, Inc. The growing popularity of cell & gene therapy, prevalence of chronic diseases is increasing and plasmid DNA has a wide range of uses in the healthcare sector are the key factors driving the growth of the market.
The field of gene therapy significantly broaden the treatment of viral infections, malignancies, hereditary illnesses, and immunotherapy. The therapy is, however, not yet widely used in clinical settings, and licenses have often only been given in particular countries. Examples of gene treatments include Spinraza, which is used to treat spinal muscular atrophy. However, government assistance, assuring sustainability, community involvement, enacting suitable regulatory legislation, and promoting entrepreneurship are vital to the success of any gene therapy programs in Africa. Hence, the growing adoption of gene therapy in the treatment of cancer is propelling the growth of the plasmid DNA contract manufacturing market.
However, the COVID-19 resulted into positive impact on the plasmid DNA contract manufacturing market. There was an increase in demand for vaccines during the COVID-19 pandemic. The market would certainly benefit from the efforts of biotechnology companies that produce COVID-19 vaccines made from plasmid DNA. In 2022, it is anticipated that the incidence of COVID-19 would increase, thus advancing the need for COVID-19 vaccinations. For instance, India recently became the first country in the world to approve a COVID-19 DNA plasmid vaccine. The ZyCoV-D vaccine has received the Drugs Controller General of India's emergency clearance, making it the sixth vaccine to receive approval in India. Furthermore, it is the only vaccine that has been approved for adolescents between the ages of 12 and 18. The fact that a DNA vaccination has been authorized for use in people for the first time, according to researchers from all around the world, makes the approval significant.
Plasmid DNA Contract Manufacturing Market Report Highlights
Plasmid DNA Contract Manufacturing Market Growth & Trends
The global plasmid DNA contract manufacturing market size is expected to reach USD 1,117.5 million by 2030, registering a CAGR of 19.3%, according to a new report by Grand View Research, Inc. The growing popularity of cell & gene therapy, prevalence of chronic diseases is increasing and plasmid DNA has a wide range of uses in the healthcare sector are the key factors driving the growth of the market.
The field of gene therapy significantly broaden the treatment of viral infections, malignancies, hereditary illnesses, and immunotherapy. The therapy is, however, not yet widely used in clinical settings, and licenses have often only been given in particular countries. Examples of gene treatments include Spinraza, which is used to treat spinal muscular atrophy. However, government assistance, assuring sustainability, community involvement, enacting suitable regulatory legislation, and promoting entrepreneurship are vital to the success of any gene therapy programs in Africa. Hence, the growing adoption of gene therapy in the treatment of cancer is propelling the growth of the plasmid DNA contract manufacturing market.
However, the COVID-19 resulted into positive impact on the plasmid DNA contract manufacturing market. There was an increase in demand for vaccines during the COVID-19 pandemic. The market would certainly benefit from the efforts of biotechnology companies that produce COVID-19 vaccines made from plasmid DNA. In 2022, it is anticipated that the incidence of COVID-19 would increase, thus advancing the need for COVID-19 vaccinations. For instance, India recently became the first country in the world to approve a COVID-19 DNA plasmid vaccine. The ZyCoV-D vaccine has received the Drugs Controller General of India's emergency clearance, making it the sixth vaccine to receive approval in India. Furthermore, it is the only vaccine that has been approved for adolescents between the ages of 12 and 18. The fact that a DNA vaccination has been authorized for use in people for the first time, according to researchers from all around the world, makes the approval significant.
Plasmid DNA Contract Manufacturing Market Report Highlights
- Cell & gene therapy dominated the market with a revenue share of 60.3% in 2022. The growing confidence of people in the dependability, efficiency, and safety of gene treatments in the treatment of a wide range of chronic and genetic disorders drives the growth of the segment.
- Based on therapeutic areas, cancer dominated the segment with a revenue share of 39.0% in 2022. The growing number of cancer cases increases the demand for cancer treatment therapies.
- Pharmaceutical and Biotechnology Companies dominated the market with a revenue share of 59.2% in 2022. There is a growing demand for innovative therapies requiring plasmid DNA. The companies investing in research also help to propel the segment market.
- Asia Pacific is anticipated to register the fastest CAGR growth of 19.9% during the forecast period. The high burden of diseases, growing cancer cases, and growing adoption of plasmid DNA for developing vaccines and drugs for various diseases are the key factors driving the growth of the market in the region
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. Therapeutic Area
1.1.3. End - user
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
1.9.3. Objective
1.9.4. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
CHAPTER 3. PLASMID DNA CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing disease prevalence
3.2.1.2. Growing Investments in Research Studies
3.2.1.3. Growing Popularity of Gene Therapy
3.2.2. Market restraint analysis
3.2.2.1. Lack of advanced infrastructure for manufacturing in certain developing countries
3.2.2.2. Quality Issues associated with Contract Manufacturing
3.2.3. Covid - 19 Impact & Recovery Analysis
3.2.4. Heat Map Analysis
3.2.5. Major Deals and Strategic Alliances Analysis
3.2.6. Industry Analysis - Porter’s
3.2.7. PESTLE Analysis
CHAPTER 4. PLASMID DNA CONTRACT MANUFACTURING MARKET: APPLICATION SEGMENT ANALYSIS
4.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
4.2. Plasmid DNA Contract Manufacturing Market: Application Market Share Analysis, 2022 & 2030
4.2.1. Gene Therapy
4.2.1.1. Gene Therapy Market, 2018 - 2030 (USD Million)
4.2.2. Immunotherapy
4.2.2.1. Immunotherapy Market, 2018 - 2030 (USD Million)
4.2.3. Others
4.2.3.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. PLASMID DNA CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA SEGMENT ANALYSIS
5.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
5.2. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2022 & 2030
5.2.1. Cancer
5.2.1.1. Cancer Market, 2018 - 2030 (USD Million)
5.2.2. Infectious Diseases
5.2.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
5.2.3. Autoimmune Diseases
5.2.3.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
5.2.4. Cardiovascular Diseases
5.2.4.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
5.2.5. Others
5.2.5.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. PLASMID DNA CONTRACT MANUFACTURING MARKET: END - USER SEGMENT ANALYSIS
6.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
6.2. Plasmid DNA Contract Manufacturing Market: End - user Market Share Analysis, 2022 & 2030
6.2.1. Pharmaceutical and Biotechnology Companies
6.2.1.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.2.2. Research Institutes
6.2.2.1. Research Institutes Market, 2018 - 2030 (USD Million)
CHAPTER 7. PLASMID DNA CONTRACT MANUFACTURING MARKET: REGIONAL ANALYSIS
7.1. Plasmid DNA Contract Manufacturing Market: Regional market share analysis, 2022 & 2030
7.2. North America
7.2.1. North America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.4. Italy
7.3.4.1. Italy Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.5. Spain
7.3.5.1. Spain Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.6. Denmark
7.3.6.1. Denmark Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Sweden Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Norway Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.9. Rest of EU
7.3.9.1. Rest of EU Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.3. India
7.4.3.1. India Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.4. Japan
7.4.4.1. Japan Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Thailand Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. South Korea Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.8. Rest of APAC
7.4.8.1. Rest of APAC Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Mexico Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Argentina Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.5. Rest of LATAM
7.5.5.1. Rest of LATAM Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.3. South Arabia
7.6.3.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.6. Rest of MEA
7.6.6.1. Rest of MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Plasmid DNA Contract Manufacturing Market: Company market share analysis, 2022 & 2030
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Charles River Laboratories
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. VGXI, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Plasmid Factory GmbH & Co. KG
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Boehringer Ingelheim Bioxellence
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. BioCina
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. ThermoFisher Scientific Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. VIVE Biotech
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. TriLink Biotechnologies
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Esco Aster Pte. Ltd
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Application
1.1.2. Therapeutic Area
1.1.3. End - user
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective
1.9.2. Objective
1.9.3. Objective
1.9.4. Objective
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
CHAPTER 3. PLASMID DNA CONTRACT MANUFACTURING MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing disease prevalence
3.2.1.2. Growing Investments in Research Studies
3.2.1.3. Growing Popularity of Gene Therapy
3.2.2. Market restraint analysis
3.2.2.1. Lack of advanced infrastructure for manufacturing in certain developing countries
3.2.2.2. Quality Issues associated with Contract Manufacturing
3.2.3. Covid - 19 Impact & Recovery Analysis
3.2.4. Heat Map Analysis
3.2.5. Major Deals and Strategic Alliances Analysis
3.2.6. Industry Analysis - Porter’s
3.2.7. PESTLE Analysis
CHAPTER 4. PLASMID DNA CONTRACT MANUFACTURING MARKET: APPLICATION SEGMENT ANALYSIS
4.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
4.2. Plasmid DNA Contract Manufacturing Market: Application Market Share Analysis, 2022 & 2030
4.2.1. Gene Therapy
4.2.1.1. Gene Therapy Market, 2018 - 2030 (USD Million)
4.2.2. Immunotherapy
4.2.2.1. Immunotherapy Market, 2018 - 2030 (USD Million)
4.2.3. Others
4.2.3.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. PLASMID DNA CONTRACT MANUFACTURING MARKET: THERAPEUTIC AREA SEGMENT ANALYSIS
5.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
5.2. Plasmid DNA Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2022 & 2030
5.2.1. Cancer
5.2.1.1. Cancer Market, 2018 - 2030 (USD Million)
5.2.2. Infectious Diseases
5.2.2.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
5.2.3. Autoimmune Diseases
5.2.3.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
5.2.4. Cardiovascular Diseases
5.2.4.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
5.2.5. Others
5.2.5.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. PLASMID DNA CONTRACT MANUFACTURING MARKET: END - USER SEGMENT ANALYSIS
6.1. Plasmid DNA Contract Manufacturing Market: Definition & Scope
6.2. Plasmid DNA Contract Manufacturing Market: End - user Market Share Analysis, 2022 & 2030
6.2.1. Pharmaceutical and Biotechnology Companies
6.2.1.1. Pharmaceutical and Biotechnology Companies Market, 2018 - 2030 (USD Million)
6.2.2. Research Institutes
6.2.2.1. Research Institutes Market, 2018 - 2030 (USD Million)
CHAPTER 7. PLASMID DNA CONTRACT MANUFACTURING MARKET: REGIONAL ANALYSIS
7.1. Plasmid DNA Contract Manufacturing Market: Regional market share analysis, 2022 & 2030
7.2. North America
7.2.1. North America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.2. U.K.
7.3.2.1. U.K. Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.4. Italy
7.3.4.1. Italy Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.5. Spain
7.3.5.1. Spain Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.6. Denmark
7.3.6.1. Denmark Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Sweden Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Norway Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.3.9. Rest of EU
7.3.9.1. Rest of EU Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.3. India
7.4.3.1. India Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.4. Japan
7.4.4.1. Japan Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Australia Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Thailand Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. South Korea Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.4.8. Rest of APAC
7.4.8.1. Rest of APAC Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Mexico Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Argentina Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.5.5. Rest of LATAM
7.5.5.1. Rest of LATAM Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.3. South Arabia
7.6.3.1. South Africa Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
7.6.6. Rest of MEA
7.6.6.1. Rest of MEA Plasmid DNA Contract Manufacturing Market, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Plasmid DNA Contract Manufacturing Market: Company market share analysis, 2022 & 2030
8.2. Company Profiles
8.2.1. Lonza
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Service benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Charles River Laboratories
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Service benchmarking
8.2.2.4. Strategic initiatives
8.2.3. VGXI, Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Service benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Plasmid Factory GmbH & Co. KG
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Service benchmarking
8.2.4.4. Strategic initiatives
8.2.5. Boehringer Ingelheim Bioxellence
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Service benchmarking
8.2.5.4. Strategic initiatives
8.2.6. BioCina
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Service benchmarking
8.2.6.4. Strategic initiatives
8.2.7. ThermoFisher Scientific Inc.
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Service benchmarking
8.2.7.4. Strategic initiatives
8.2.8. VIVE Biotech
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Service benchmarking
8.2.8.4. Strategic initiatives
8.2.9. TriLink Biotechnologies
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Service benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Esco Aster Pte. Ltd
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Service benchmarking
8.2.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of Secondary sources
Table 2 List of Abbreviations
Table 1 List of Secondary sources
Table 2 List of Abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Plasmid DNA Contract Manufacturing market snapshot (2022)
Fig. 10 Plasmid DNA Contract Manufacturing market segmentation
Fig. 11 Heat map analysis
Fig. 12 Parent market outlook
Fig. 13 Ancillary market outlook
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Plasmid DNA Contract Manufacturing market Application outlook: Segment dashboard
Fig. 19 Plasmid DNA Contract Manufacturing market: Application movement analysis
Fig. 20 Cell & Gene Therapy market, 2018 - 2030 (USD Million)
Fig. 21 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 22 Others market, 2018 - 2030 (USD Million)
Fig. 23 Plasmid DNA Contract Manufacturing market Therapeutic Area outlook: Segment dashboard
Fig. 24 Plasmid DNA Contract Manufacturing market: Therapeutic Area movement analysis
Fig. 25 Cancer market, 2018 - 2030 (USD Million)
Fig. 26 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 27 Autoimmune Diseases market, 2018 - 2030 (USD Million)
Fig. 28 Cardiovascular Diseases market, 2018 - 2030 (USD Million)
Fig. 29 Others market, 2018 - 2030 (USD Million)
Fig. 30 Plasmid DNA Contract Manufacturing market End-user outlook: Segment dashboard
Fig. 31 Plasmid DNA Contract Manufacturing market: End-user movement analysis
Fig. 32 Pharmaceutical and Biotechnology Companies market, 2018 - 2030 (USD Million)
Fig. 33 Research Institutes market, 2018 - 2030 (USD Million)
Fig. 34 Regional market: Key takeaways
Fig. 35 Plasmid DNA Contract Manufacturing market: Regional movement analysis
Fig. 36 North America. market, 2018 - 2030 (USD Million)
Fig. 37 U.S. market, 2018 - 2030 (USD Million)
Fig. 38 Canada market, 2018 - 2030 (USD Million)
Fig. 39 Europe market, 2018 - 2030 (USD Million)
Fig. 40 UK market, 2018 - 2030 (USD Million)
Fig. 41 Germany market, 2018 - 2030 (USD Million)
Fig. 42 France market, 2018 - 2030 (USD Million)
Fig. 43 Italy market, 2018 - 2030 (USD Million)
Fig. 44 Spain market, 2018 - 2030 (USD Million)
Fig. 45 Denmark market, 2018 - 2030 (USD Million)
Fig. 46 Sweden market, 2018 - 2030 (USD Million)
Fig. 47 Norway market, 2018 - 2030 (USD Million)
Fig. 48 Rest of EU market, 2018 - 2030 (USD Million)
Fig. 49 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 50 Japan market, 2018 - 2030 (USD Million)
Fig. 51 China market, 2018 - 2030 (USD Million)
Fig. 52 India market, 2018 - 2030 (USD Million)
Fig. 53 Australia market, 2018 - 2030 (USD Million)
Fig. 54 Thailand market, 2018 - 2030 (USD Million)
Fig. 55 South Korea market, 2018 - 2030 (USD Million)
Fig. 56 Rest of APAC market, 2018 - 2030 (USD Million)
Fig. 57 Latin America market, 2018 - 2030 (USD Million)
Fig. 58 Brazil market, 2018 - 2030 (USD Million)
Fig. 59 Mexico market, 2018 - 2030 (USD Million)
Fig. 60 Argentina market, 2018 - 2030 (USD Million)
Fig. 61 Rest of LATAM market, 2018 - 2030 (USD Million)
Fig. 62 MEA market, 2018 - 2030 (USD Million)
Fig. 63 South Africa market, 2018 - 2030 (USD Million)
Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 65 UAE market, 2018 - 2030 (USD Million)
Fig. 66 Kuwait market, 2018 - 2030 (USD Million)
Fig. 67 Rest of MEA market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 Plasmid DNA Contract Manufacturing market snapshot (2022)
Fig. 10 Plasmid DNA Contract Manufacturing market segmentation
Fig. 11 Heat map analysis
Fig. 12 Parent market outlook
Fig. 13 Ancillary market outlook
Fig. 14 Market driver relevance analysis (Current & future impact)
Fig. 15 Market restraint relevance analysis (Current & future impact)
Fig. 16 Porter’s five forces analysis
Fig. 17 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 18 Plasmid DNA Contract Manufacturing market Application outlook: Segment dashboard
Fig. 19 Plasmid DNA Contract Manufacturing market: Application movement analysis
Fig. 20 Cell & Gene Therapy market, 2018 - 2030 (USD Million)
Fig. 21 Immunotherapy market, 2018 - 2030 (USD Million)
Fig. 22 Others market, 2018 - 2030 (USD Million)
Fig. 23 Plasmid DNA Contract Manufacturing market Therapeutic Area outlook: Segment dashboard
Fig. 24 Plasmid DNA Contract Manufacturing market: Therapeutic Area movement analysis
Fig. 25 Cancer market, 2018 - 2030 (USD Million)
Fig. 26 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 27 Autoimmune Diseases market, 2018 - 2030 (USD Million)
Fig. 28 Cardiovascular Diseases market, 2018 - 2030 (USD Million)
Fig. 29 Others market, 2018 - 2030 (USD Million)
Fig. 30 Plasmid DNA Contract Manufacturing market End-user outlook: Segment dashboard
Fig. 31 Plasmid DNA Contract Manufacturing market: End-user movement analysis
Fig. 32 Pharmaceutical and Biotechnology Companies market, 2018 - 2030 (USD Million)
Fig. 33 Research Institutes market, 2018 - 2030 (USD Million)
Fig. 34 Regional market: Key takeaways
Fig. 35 Plasmid DNA Contract Manufacturing market: Regional movement analysis
Fig. 36 North America. market, 2018 - 2030 (USD Million)
Fig. 37 U.S. market, 2018 - 2030 (USD Million)
Fig. 38 Canada market, 2018 - 2030 (USD Million)
Fig. 39 Europe market, 2018 - 2030 (USD Million)
Fig. 40 UK market, 2018 - 2030 (USD Million)
Fig. 41 Germany market, 2018 - 2030 (USD Million)
Fig. 42 France market, 2018 - 2030 (USD Million)
Fig. 43 Italy market, 2018 - 2030 (USD Million)
Fig. 44 Spain market, 2018 - 2030 (USD Million)
Fig. 45 Denmark market, 2018 - 2030 (USD Million)
Fig. 46 Sweden market, 2018 - 2030 (USD Million)
Fig. 47 Norway market, 2018 - 2030 (USD Million)
Fig. 48 Rest of EU market, 2018 - 2030 (USD Million)
Fig. 49 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 50 Japan market, 2018 - 2030 (USD Million)
Fig. 51 China market, 2018 - 2030 (USD Million)
Fig. 52 India market, 2018 - 2030 (USD Million)
Fig. 53 Australia market, 2018 - 2030 (USD Million)
Fig. 54 Thailand market, 2018 - 2030 (USD Million)
Fig. 55 South Korea market, 2018 - 2030 (USD Million)
Fig. 56 Rest of APAC market, 2018 - 2030 (USD Million)
Fig. 57 Latin America market, 2018 - 2030 (USD Million)
Fig. 58 Brazil market, 2018 - 2030 (USD Million)
Fig. 59 Mexico market, 2018 - 2030 (USD Million)
Fig. 60 Argentina market, 2018 - 2030 (USD Million)
Fig. 61 Rest of LATAM market, 2018 - 2030 (USD Million)
Fig. 62 MEA market, 2018 - 2030 (USD Million)
Fig. 63 South Africa market, 2018 - 2030 (USD Million)
Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 65 UAE market, 2018 - 2030 (USD Million)
Fig. 66 Kuwait market, 2018 - 2030 (USD Million)
Fig. 67 Rest of MEA market, 2018 - 2030 (USD Million)
